• 2021-03-30
    On March 30, CSL Behring, a global leader in biotherapeutics, announced at the CSL Behring Blood Products Retail Summit that it has partnered with Qingdao Baheal Medical Co. Ltd. ("Baheal Medical"). The two companies will work together to provide effective and accessible drug solutions to Chinese patients.This is another important product of CSL Behring undertaken by Baheal's third-party commercialization platform, following the cooperation of human albumin products AlbuRx and Behring®. By now,
  • 2021-03-29
    On March 29, Roche China and Qingdao Baheal Medical Co. Ltd. ("Baheal Medical") announced partnership in oncology field. Roche has granted the marketing rights of its two major oncology products, Xeloda® (capecitabine tablets) and Tarceva® (erlotinib hydrochloride tablets), to Baheal Medical in mainland China to promote the market layout of oncology drugs, enhance product accessibility and serve the majority of oncology patients in China.
  • 2021-03-23
    On March 23, Baheal Pharmaceutical Group and Shandong First Medical University signed a school-enterprise strategic cooperation agreement in Jinan, Shandong Province. Baheal Pharmaceutical Group and Shandong First Medical University will work in the fields of talent training, scientific research, social services etc., to build a "production-academia-research-application" whole industry chain, and contribute to the development of medical talent training and medical research innovation strength an
  • 2021-03-20
    On March 20, Qingdao Baheal Medical Co., Ltd (hereinafter referred to as "Baheal Medical") opened the flagship store of its new retail sub-brand Cute Camel 2.0 in Qingdao, Shandong Province. As the first truly fashionable health store in China, Cute Camel, the Chinese version of Matsumoto Kiyoshi, can realize the same category of operation as Japanese drugstore, with skin care products, drugs, health food, etc. operating and serving in the same space. The opening of this upgraded offline store m
  • 2021-02-04
    On February 3, the result of the fourth batch of national volume-based procurement (VBP) was announced, and the competition results of the antidepressant drug duloxetine were settled. The results show that Qingdao Baheal Pharmaceutical Co., Ltd (Baheal Pharma), a subsidiary of Baheal Pharmaceutical Group, won the competition with the price of RMB 8.25 per box for Duloxetine Hydrochloride Enteric Capsules Nishu (20mg*14 capsules).
Back to Top